Form 4 for VVOS Vivos Therapeutics, Inc.
Accepted 2022-12-28 00:00:00 ET · period of report 2022-12-23 · accession 0001493152-22-036727 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-12-28 | 2022-12-23 | VVOS | Huntsman Ronald Kirk | CEO, Dir, 10% | P - Purchase | $0.5 | +20.0K | 47.5K | +73% | +$10.0K |
| DM | 2022-12-28 | 2022-12-23 | VVOS | Huntsman Ronald Kirk | CEO, Dir, 10% | A - Grant | $0.48 | +483.3K | 333.3K | New | +$232.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-23 | P | A | 20,000 | $0.5 | 47,500 | D | — | — | (F1) Shares held by Coronado V Partners, LLC, of which the reporting person is a member and manager. |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-12-23 | A | A | 150,000 | $0.48 | 483,334 | D | $0.48 · — to 2027-12-23 | 483,334 Common Stock | (F3) 150,000 stock options granted on December 23, 2022. One-fifth vested immediately and one-fifth vests annually on each anniversary date through December 23, 2026. |
| 3 | Derivative | Stock Option (Right to Buy) | 2022-12-23 | A | A | 333,334 | $0.48 | 333,334 | D | $0.48 · — to 2027-12-23 | 333,334 Common Stock | (F2) 333,334 fully vested stock options granted on December 23, 2022. |